Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Sinopharm Group Co Ltd banner

Sinopharm Group Co Ltd
XBER:X2S

Watchlist Manager
Sinopharm Group Co Ltd Logo
Sinopharm Group Co Ltd
XBER:X2S
Watchlist
Price: 2.309 EUR -3.35% Market Closed
Market Cap: €7.2B
Write Note Create Alert Ask AI

Wall St Price Targets

X2S Price Targets Summary
Sinopharm Group Co Ltd

Wall Street analysts forecast X2S stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for X2S is 3.232 EUR with a low forecast of 2.558 EUR and a high forecast of 4.219 EUR.

X2S Lowest Forecast
Wall Street Target
€2.558
11% Upside
X2S Average Forecast
Wall Street Target
€3.232
40% Upside
X2S Highest Forecast
Wall Street Target
€4.219
83% Upside
Lowest Forecast
Price Target
2.558 EUR
11% Upside
Average Forecast
Price Target
3.232 EUR
40% Upside
Highest Forecast
Price Target
4.219 EUR
83% Upside
Sinopharm Group Co Ltd Competitors:
Price Targets
4337
Pia Corp
41% Upside
4337
Pia Corp
41% Upside

Revenue
Forecast

13% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
13% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 4%.

What are analyst estimates?

Gross Profit
Forecast

12% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
12% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 9%.

What are analyst estimates?

Operating Income
Forecast

11% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
11% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 7%.

What are analyst estimates?

Pre-Tax Income
Forecast

12% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
12% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is 7%.

What are analyst estimates?

Net Income
Forecast

11% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
11% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 7%.

What are analyst estimates?

Continue X2S Research

Summary
X2S intrinsic value, competitors valuation, and company profile.
DCF Valuation
X2S stock valuation using Discount Cash Flow valuation method.
Relative Valuation
X2S stock valuation using valuation multiples.
Wall St Estimates
X2S price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
X2S stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Sinopharm Group Co Ltd listings:
OTC • USD
SHTDF
 OTC • USD
SHTDY
 HKEX • HKD
1099
 F • EUR
X2S
 F • EUR
X2S1
 XMUN • EUR
X2S
 SWB • EUR
X2S
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is X2S's stock price target?
Price Target
3.232 EUR

According to Wall Street analysts, the average 1-year price target for X2S is 3.232 EUR with a low forecast of 2.558 EUR and a high forecast of 4.219 EUR.

What is the Revenue forecast for Sinopharm Group Co Ltd?
Projected CAGR
4%

Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 4%.

What is the Gross Profit forecast for Sinopharm Group Co Ltd?
Projected CAGR
9%

Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 9%.

What is the Operating Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
7%

Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 7%.

What is the Pre-Tax Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
7%

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is 7%.

What is the Net Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
7%

Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 7%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett